JP6483148B2 - ＨＰＴＰ−β阻害剤 - Google Patents

ＨＰＴＰ−β阻害剤 Download PDF

Info

Publication number
JP6483148B2
JP6483148B2 JP2016556997A JP2016556997A JP6483148B2 JP 6483148 B2 JP6483148 B2 JP 6483148B2 JP 2016556997 A JP2016556997 A JP 2016556997A JP 2016556997 A JP2016556997 A JP 2016556997A JP 6483148 B2 JP6483148 B2 JP 6483148B2
Authority
JP
Japan
Prior art keywords
substituted
compound
bond
unsubstituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016556997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511305A (ja
JP2017511305A5 (enExample
Inventor
ジョン ジャヌス，
ジョン ジャヌス，
ジェイムズ コップ，
ジェイムズ コップ，
ケビン ピータース，
ケビン ピータース，
Original Assignee
エアーピオ セラピューティクス インコーポレイテッド
エアーピオ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアーピオ セラピューティクス インコーポレイテッド, エアーピオ セラピューティクス インコーポレイテッド filed Critical エアーピオ セラピューティクス インコーポレイテッド
Publication of JP2017511305A publication Critical patent/JP2017511305A/ja
Publication of JP2017511305A5 publication Critical patent/JP2017511305A5/ja
Application granted granted Critical
Publication of JP6483148B2 publication Critical patent/JP6483148B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016556997A 2014-03-14 2015-03-13 ＨＰＴＰ−β阻害剤 Active JP6483148B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953680P 2014-03-14 2014-03-14
US61/953,680 2014-03-14
PCT/US2015/020425 WO2015138882A1 (en) 2014-03-14 2015-03-13 Hptp-beta inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018246712A Division JP6661744B2 (ja) 2014-03-14 2018-12-28 ＨＰＴＰ−β阻害剤

Publications (3)

Publication Number Publication Date
JP2017511305A JP2017511305A (ja) 2017-04-20
JP2017511305A5 JP2017511305A5 (enExample) 2018-04-12
JP6483148B2 true JP6483148B2 (ja) 2019-03-13

Family

ID=54068203

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016556997A Active JP6483148B2 (ja) 2014-03-14 2015-03-13 ＨＰＴＰ−β阻害剤
JP2018246712A Active JP6661744B2 (ja) 2014-03-14 2018-12-28 ＨＰＴＰ−β阻害剤
JP2019077696A Withdrawn JP2019108407A (ja) 2014-03-14 2019-04-16 ＨＰＴＰ−β阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018246712A Active JP6661744B2 (ja) 2014-03-14 2018-12-28 ＨＰＴＰ−β阻害剤
JP2019077696A Withdrawn JP2019108407A (ja) 2014-03-14 2019-04-16 ＨＰＴＰ−β阻害剤

Country Status (5)

Country Link
US (3) US9994560B2 (enExample)
EP (1) EP3116503A4 (enExample)
JP (3) JP6483148B2 (enExample)
CN (1) CN106456614A (enExample)
WO (1) WO2015138882A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371865B1 (en) 2006-04-07 2017-07-12 Aerpio Therapeutics, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
RU2014146121A (ru) * 2009-01-12 2015-06-10 Аэрпио Терапьютикс Инк. Способы лечения синдрома сосудистой утечки
EP3556367A1 (en) 2009-07-06 2019-10-23 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in the treatment of cancer or metastasis
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
BR112015023753A2 (pt) 2013-03-15 2017-07-18 Aerpio Therapeutics Inc composições, formulações e métodos para o tratamento de doenças oculares
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
ES2981607T3 (es) * 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
JP7107914B2 (ja) 2016-07-20 2022-07-27 アイポイント ファーマシューティカルズ， インコーポレイテッド ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
JP2021515035A (ja) * 2018-02-26 2021-06-17 エアーピオ ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰβ阻害剤を使用して糖尿病性腎症を処置する方法
EP3820458A1 (en) * 2018-07-13 2021-05-19 Susan Quaggin Ve-ptp inhibition in glaucoma
PL3873605T3 (pl) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Związki hamujące integrynę alfa4beta7
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
PT3873884T (pt) 2018-10-30 2025-02-25 Gilead Sciences Inc Derivados de 3-(quinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidina-2,4-diona como inibidores da integrina alfa4beta7 para o tratamento de doenças inflamatórias
AU2020259450A1 (en) * 2019-04-18 2021-11-18 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of Tie-2
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint, Inc. Tie-2 activators targeting the schlemm's canal
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
EP4051267A4 (en) 2019-10-29 2023-12-06 EyePoint Pharmaceuticals, Inc. TIE-2 SMALL MOLECULE ACTIVATORS
CN113060789A (zh) * 2019-12-31 2021-07-02 大连乾丰生物科技有限公司 一种海蜇池塘水底质改良剂
US20240190857A1 (en) * 2020-12-18 2024-06-13 EyePoint Pharmaceuticals, Inc. Methods for manufacture of small molecule activators of tie-2

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221584A (en) 1979-02-09 1980-09-09 Chevron Research Company Herbicidal and plant-growth-regulating N-(heterocyclyl)-methylacetanilides
US4735961A (en) 1984-05-07 1988-04-05 Merck & Co., Inc. Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety
UA55381C2 (uk) * 1995-01-27 2003-04-15 Ново Нордіск А/С Похідні пептиду (варіанти), що здатні вивільнювати гормон росту, фармацевтична композиція (варіанти), спосіб стимулювання вивільнення гормону росту з гіпофіза, способи підвищення швидкості і темпу росту та виробництва молока або вовни, спосіб лікування нездужань
ATE273384T1 (de) 1995-04-06 2004-08-15 Regeneron Pharma Tie-2 liganden, herstellungsverfahren und verwendung
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
WO1998018914A1 (en) 1996-10-31 1998-05-07 Duke University Soluble tie2 receptor
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
DE60003011T2 (de) 1999-03-26 2004-04-08 Regeneron Pharmaceuticals, Inc. Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
DK1292335T3 (da) 2000-06-23 2007-09-17 Bayer Schering Pharma Ag Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II)
WO2003034990A2 (en) 2001-10-25 2003-05-01 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
DE60315603T2 (de) * 2002-02-25 2008-05-21 Eli Lilly And Co., Indianapolis Modulatoren von peroxisome proliferator-aktivierten rezeptoren
WO2003084565A2 (en) 2002-04-08 2003-10-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Ve-ptp as regulator of ve-cadherin mediated processes or disorders
RU2376029C2 (ru) 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
AR046510A1 (es) 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
LT2653465T (lt) 2004-03-15 2016-09-12 Janssen Pharmaceutica Nv Opioidinio receptoriaus moduliatoriai
DE602005016659D1 (de) * 2004-03-18 2009-10-29 R Tech Ueno Ltd Wässrige zusammensetzung mit einem thiazol-derivat
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
DK1771474T3 (da) 2004-07-20 2010-05-31 Genentech Inc Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
DK2457578T3 (en) 2004-09-28 2015-12-07 Aprogen Inc A chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in the treatment of erectile dysfunction of the penis
BRPI0519596B1 (pt) 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
CA2633211A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
EP2371865B1 (en) 2006-04-07 2017-07-12 Aerpio Therapeutics, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) * 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
CA2693383C (en) 2006-10-27 2017-03-28 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
RU2014146121A (ru) * 2009-01-12 2015-06-10 Аэрпио Терапьютикс Инк. Способы лечения синдрома сосудистой утечки
KR20110123789A (ko) 2009-03-03 2011-11-15 알콘 리서치, 리미티드 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
JP5583146B2 (ja) 2009-03-03 2014-09-03 アルコン リサーチ， リミテッド レセプターチロシンキナーゼ阻害（ＲＴＫｉ）化合物の眼への送達のための薬学的組成物
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
EP3556367A1 (en) * 2009-07-06 2019-10-23 Aerpio Therapeutics, Inc. Benzosulfonamide derivatives, compositions thereof, and their use in the treatment of cancer or metastasis
CN102612367B (zh) 2009-11-06 2014-02-19 阿尔皮奥治疗学股份有限公司 脯氨酰羟化酶抑制剂
US20110319455A1 (en) 2010-04-19 2011-12-29 Bruce Steven Klein Antifungal Treatment
ES2649340T3 (es) 2010-07-12 2018-01-11 Threshold Pharmaceuticals, Inc. Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
KR101823924B1 (ko) * 2010-10-07 2018-01-31 에르피오 세러퓨틱스 인코포레이티드 안구 부종, 신생혈관화 및 관련 질환의 치료를 위한 조성물 및 방법
EP2857032A3 (en) 2010-12-02 2015-07-15 Maruzen Pharmaceuticals Co., Ltd. Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition
MX347226B (es) 2011-10-13 2017-04-19 Aerpio Therapeutics Inc Tratamiento de enfermedad ocular.
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20130190324A1 (en) 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
US20150071941A1 (en) 2012-04-13 2015-03-12 The Johns Hopkins University Treatment of ischemic retinopathies
NZ702201A (en) 2012-07-13 2018-01-26 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
HUE039520T2 (hu) 2012-07-31 2019-01-28 Univ Texas Eljárások és készítmények hasnyálmirigy béta sejtek kialakulásának in vivo indukálására
NZ706853A (en) 2012-10-11 2018-04-27 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
CA2890471C (en) 2012-11-08 2021-07-27 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
EP2922572A1 (en) 2012-11-23 2015-09-30 AB Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
BR112015023753A2 (pt) 2013-03-15 2017-07-18 Aerpio Therapeutics Inc composições, formulações e métodos para o tratamento de doenças oculares
WO2014165963A1 (en) 2013-04-11 2014-10-16 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
EP3010525A1 (en) 2013-06-20 2016-04-27 Novartis AG Use of a vegf antagonist in treating choroidal neovascularisation
WO2014203183A1 (en) 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating macular edema
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
WO2015004616A1 (en) 2013-07-11 2015-01-15 Novartis Ag Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
US20160159893A1 (en) 2013-07-11 2016-06-09 Gabriela Burian Use of a VEGF Antagonist in Treating Retinopathy of Prematurity
EP3381940B1 (en) 2013-07-29 2022-09-07 Samsung Electronics Co., Ltd. Anti-ang2 antibody
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
ES2731531T3 (es) 2013-10-01 2019-11-15 Sphingotec Gmbh Método para predecir el riesgo de experimentar un episodio cardiaco adverso grave
PT3062811T (pt) 2013-11-01 2019-06-11 Regeneron Pharma Intervenções à base de angiopoietina para o tratamento da malária cerebral
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
JP2015199733A (ja) 2014-04-04 2015-11-12 国立大学法人東北大学 眼圧降下剤
US9719135B2 (en) 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
WO2016049183A1 (en) 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
TWI705827B (zh) 2014-11-07 2020-10-01 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
JP6661744B2 (ja) 2020-03-11
US20210130341A1 (en) 2021-05-06
WO2015138882A1 (en) 2015-09-17
US20150259335A1 (en) 2015-09-17
EP3116503A4 (en) 2017-08-23
JP2019048894A (ja) 2019-03-28
EP3116503A1 (en) 2017-01-18
US9994560B2 (en) 2018-06-12
US20180354937A1 (en) 2018-12-13
JP2019108407A (ja) 2019-07-04
JP2017511305A (ja) 2017-04-20
CN106456614A (zh) 2017-02-22
US10858354B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
JP6483148B2 (ja) ＨＰＴＰ−β阻害剤
JP6865254B2 (ja) 眼疾患を処置するための組成物、製剤、および方法
KR101823924B1 (ko) 안구 부종, 신생혈관화 및 관련 질환의 치료를 위한 조성물 및 방법
KR20180054677A (ko) Tie-2의 활성화제로 안내압을 치료하는 방법
US20170172959A1 (en) D-serine for the treatment of visual system disorders
US12187715B2 (en) Small molecule activators of Tie-2
KR20120081585A (ko) 안질환을 치료하기 위한 이소티오졸
CA3138682A1 (en) Tie-2 activators targeting the schlemm's canal
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
EP4518859A1 (en) Relative undersupply of an amyloid beta aggregation inhibitor for improved detoxifying effects
WO2021039791A1 (ja) 血管新生関連疾患の予防又は治療用医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190213

R150 Certificate of patent or registration of utility model

Ref document number: 6483148

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250